Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
metoclopramide is developed for 1 unique indication across 1 therapeutic area.
Therapeutic Area
Condition
Phase
Gastrointestinal disorders
Gastric atony
✓ Approved
Related Research Articles
PubMedRevista de gastroenterologia de Mexico (English)2026-06-09
High-dose metoclopramide versus placebo for gastroduodenal visualization during endoscopy in patients with acute upper gastrointestinal bleeding. A triple-blind, randomized clinical trial.
Herrera-Elizondo J L JL, Jiménez-Castillo R A RA, García-Compeán D D, Jaquez-Quintana J O JO et al.
The usefulness of metoclopramide for improving endoscopic visualization in upper gastrointestinal bleeding (UGIB) is controversial. Our primary aim was to evaluate the utility of metoclopramide 20 mg/IV for endoscopic visualization in UGIB of ≤ 24 h. The need for a repeat endoscopy and length of hospital stay were also analyzed.
Patients were randomized 1:1 to receive placebo (group A) or metoclopramide 20 mg/IV (group B) and undergo endoscopy 30-120 min later. Demographics, etiology, and hospital stay were evaluated. The percentage of gastroduodenal visualization was assessed through the modified Avgerinos score. A blinded, experienced endoscopist reviewed the endoscopic recordings.
Fifty patients, 27 men and 23 women, were included. Mean patient age was 60 years, and each group was made up of 25 patients. The time from admission to endoscopy in group A was 14:21 h (SD ± 5.35) and 14:54 h (SD ± 5.83) in group B (p = 0.83). The modified Avgerinos score was 7.00 (5.00-8.00) in group A and 7.00 (6.50-8.00) in group B (p = 0.282). The difference in the modified Avgerinos score was not statistically significant in the patients with variceal and ulcerous etiologies (p = 0.705 and p = 0.721, respectively). A repeat endoscopy was required in 3 group A patients and 4 group B patients (p = 0.684). Hospital stay for group A was 7.0 days (SD ± 3.08) and 7.32 days (SD ± 4.31) for group B (p = 0.764).
Metoclopramide 20 mg/IV before endoscopy did not improve endoscopic visualization, the need for a repeat endoscopy, or length of hospital stay in patients with UGIB.
PubMedJournal of Alzheimer's disease : JAD2026-06-09
Semaglutide showed limited improvements in patients with Alzheimer's disease: Revisiting the evoke and evoke + clinical trials.
Hölscher Christian C
BackgroundSemaglutide is a glucagon-like peptide-1 analog that is on the market to treat type 2 diabetes and weight loss (Ozempic, Wegovy). Two phase 3 clinical trials have been conducted, Evoke and Evoke+, testing the drug in patients with Alzheimer's disease. The trial management presented results of the intermediate readout at week 104 of the CDR-SB scores, which were negative. On the basis of that, the management decided to declare the trials a failure. However, data from week 130 and 156 had not been statistically analyzed.ObjectiveWhen evaluating time points 130 and 156, several results show a separation between drug group and placebo group with semaglutide showing better results.MethodsUsing the means, converting the SEMs to SDs and numbers of patients per group, I analyzed the results using the Welch T-test (two-tailed), which does not assume equal SD.ResultsThe ADCS-ADL-MCI test, Evoke trial, week 130, did show a significant difference, p = 0.0039. Other test such as the ADAS-cog-13 results show trends towards improvement by semaglutide at week 156. Cerebrospinal fluid biomarker analyses showed significant differences in some AD markers, too.ConclusionsThe results did show some limited drug effects at later time points of the trials. However, Semaglutide has been designed to stay in the blood for a long time and therefore does not cross the blood-brain barrier readily. Novel GLP-1 type drugs that can cross the blood-brain barrier easily may show superior protective effects in AD patients.
Resting angle correction beyond aesthetics: a retrospective cohort study demonstrating its role in nasal valve repair.
Daoud Mahmoud M, Fufezan Maria Louise ML, Bahaa-Eddin Walid W, Luana-Maria Gherasie G et al.
The resting angle forms between the lateral crus of the lower lateral cartilage (LLC) and the upper lateral cartilage. While conventional nasal valve repair relies on cartilage grafting for reinforcement of these structures, the functional significance of resting angle adjustment remains underexplored. Objectives & Hypotheses: We describe a technique to reposition the LLC, adjusting the resting angle to support the lateral nasal wall and restore external nasal valve (ENV) function without grafts, with the hypothesis that this approach improves functional and aesthetic outcomes.
Retrospective cohort study.
We retrospectively identified patients with ENV collapse-related nasal obstruction who underwent the described surgery. Pre- and postoperative Peak Nasal Inspiratory Flow (PNIF) measurements and FACE-Q scores were compared to evaluate functional and aesthetic improvement, respectively.
Thirty patients (22 female, 8 male) were included. Postoperatively, median PNIF increased from 74.0 L/min (IQR: 73.0-76.0; 95% CI: 72.5-75.5) to 96.0 L/min (IQR: 93.0-97.0; 95% CI: 94.0-97.5), and median FACE-Q Satisfaction with nose scores from 17 (IQR: 16.0-18.0; 95% CI: 16.0-17.5) to 37 (IQR: 35.0-38.0; 95% CI: 36.5-37.5); both improvements were statistically significant (p<0.001).
Resting angle correction may not only improve aesthetics, but also stabilize the lateral nasal wall to prevent or repair ENV collapse.
Case Report: Oral-Nasal Damage in a Person Using Fentanyl and Xylazine.
Kmiec Julie J, Choby Garret G
Xylazine, an alpha-2-adrenergic agonist, was added to illicitly manufactured fentanyl within the past decade. Intranasal drug use is common and associated with damage to nasal structures and the palate. There have been no case reports detailing intranasal damage secondary to fentanyl and xylazine use.
We present a case of a 39-year-old woman with a long history of intranasal opioid use and, more recently, xylazine use who presented for treatment due to nasal septum perforation and oral-nasal fistulas. She started treatment for opioid use disorder and was referred to otolaryngology for further examination and treatment of palate damage thought to be secondary to intranasal fentanyl and xylazine use. She exhibited severe damage to her palate, nasal structures, and skull base.
This case illustrates damage to the nose, palate, and skull base, likely secondary to co-use of fentanyl and xylazine intranasally. It is important for clinicians to recognize that nasal damage may result from fentanyl and xylazine use and refer to appropriate substance use disorder and otolaryngology treatment to prevent further destruction.
Dermatosurgical pearls: the East-West advancement flap for reconstruction of primary defects following skin cancer excision in the nasal region.
Kordeva Simona S, Tchernev Konstantin Georgiev KG, Tchernev Georgi G
A 62-year-old male presented to the dermatology department with a primary complaint of an achromatic tumorous lesion protruding above the surrounding skin, with central atrophy, irregular borders, and visible telangiectasias, located on the nasal distal third, slightly toward the left nasal dorsum. Based on the clinical presentation, basal cell carcinoma was suspected and surgical excision under local anesthesia was recommended. [...].
PubMedJPMA. The Journal of the Pakistan Medical Association2026-06-09
Immoderate perfume use leading to non-keratinising sinonasal squamous cell carcinoma with bone and lung metastases.
Zia Shamail S, Shamail Farozaan F, Zia Fazail F, Uddin Naeem N et al.
Squamous cell carcinoma (SCC) of the sinonasal tract (SNSCC) is a cancerous epithelial tumour which originates from the epithelium surface lining the nasal cavity and paranasal sinuses and shows squamous differentiation. Here, we report the case of a patient who had the habit of soaking cotton cloth at night with perfume and spreading it over his face and sleeping for around eight hours in this position. The patient had been doing this for 30 years without any gap and presented with complaints of nose bleed and difficulty in breathing since three to four months. Upon scanning of the face, a polypoidal lesion was seen in the left nasal cavity causing partial obstruction of the nasal cavity. Biopsy of the nasal mass confirmed the presence of neoplastic lesions positive for cytokeratin 5/6 diagnosed as non-keratinising SCC. Upon further evaluation of symptoms, metastases in bones and lungs were also confirmed.